ICON (ICLR) Akcija Cena
ICON Cena
Pēdējos 19 gados ICON ieņēmumi auga par 16,5 % gadā un sasniedza 8,25 B USD. Peļņa uz akciju auga par 4,4 % gadā pēdējos 19 gados. ICON neto marža 2,8 % ir pārsvarā stabila salīdzinājumā ar 2,8 % pirms dažiem gadiem. ICON 12 mēnešu konsensa mērķa cena ir 175,00 USD, ap zem kursu par 13,8 %. No 24 analītiķiem 15 iesaka pirkt — kopējais konsenss ir Pirkt.
ICON akcijas cena
Iegūstiet šos datus caur Eulerpool API
100 000 pieprasījumu/mēn. bez maksas · bez kartes
ICON biznesa modelis un akciju analīze
Bieži uzdotie jautājumi par ICON akciju
The main competitors of ICON PLC in the market include other Contract Research Organizations (CROs) such as Covance Inc., QuintilesIMS Holdings Inc., and PAREXEL International Corporation. These companies provide similar services and solutions in the clinical research and development industry, offering competition to ICON PLC's global presence and expertise.
ICON PLC, also known as ICON, is a well-established global provider of clinical research and development services to the pharmaceutical, biotechnology, and medical device industries. Founded in 1990 in Dublin, Ireland, ICON has since expanded its operations worldwide, with offices in over 40 countries. The company offers various services, including clinical trial management, data management and analysis, regulatory support, and post-market surveillance. With a strong focus on innovation and expertise, ICON has successfully collaborated with numerous healthcare organizations to accelerate the development of innovative therapies and improve patient outcomes. Due to its vast experience and industry reputation, ICON PLC continues to be a trusted partner in advancing healthcare solutions globally.
The business model of ICON PLC is centered around providing clinical research services to pharmaceutical, biotechnology, and medical device companies. ICON offers a range of services including clinical trial management, data collection and analysis, regulatory consulting, and patient recruitment. They help their clients with the development and commercialization of new drugs and treatments by conducting clinical trials and ensuring regulatory compliance. With a strong focus on innovation and expertise in the field, ICON PLC has established itself as a trusted partner for the life sciences industry.
ICON PLC is primarily active in the pharmaceutical, biotechnology, and medical device industries.
ICON PLC, a leading clinical research organization, has achieved significant milestones throughout its history. The company's accomplishments include becoming a key player in the development and execution of clinical trials worldwide. ICON PLC has successfully expanded its global footprint, delivering exceptional services in over 100 countries. With a strong focus on innovation and technology, the company has pioneered industry-leading solutions to enhance clinical trial processes and improve patient outcomes. ICON PLC's dedication to excellence has resulted in numerous accolades and recognition within the pharmaceutical and biotechnology industries. By consistently delivering high-quality results and establishing strategic partnerships, ICON PLC has solidified its reputation as a trusted and influential player in the field of clinical research.
ICON PLC is primarily present in various countries and regions globally. With a strong international presence, the company operates in multiple key markets, including the United States, United Kingdom, Ireland, Europe, Asia-Pacific, and the Middle East. This global footprint enables ICON PLC to cater to clients worldwide and deliver its comprehensive range of professional services.
ICON PLC is a leading global provider of clinical research services to pharmaceutical, biotechnology, and medical device industries. ICON PLC is guided by a set of core values and corporate philosophy that focuses on innovation, integrity, collaboration, and excellence. The company's commitment to delivering high-quality research and development solutions, while maintaining ethical practices, has made it a trusted partner for successful clinical trials. With its dedication to advancing healthcare and improving patient outcomes, ICON PLC continues to be a respected and influential player in the industry.
Analītiķi pašlaik nosaka vidējo ICON akcijas mērķa cenu 170,64 USD (mediāna: 175,00 USD), kas ir -16,0 % pret pēdējo cenu. Konsenss balstās uz 24 analītiķu vērtējumiem.
24 analītiķi pašlaik vērtē ICON akciju: 15 iesaka pirkt, 9 turēt un 0 pārdot. 2026. gadam analītiķi sagaida, ka ICON gūs 8,16 B USD ieņēmumus un 11,47 USD peļņu uz akciju.
Pēc pašreizējā kursa ICON akcija maksā 180,75 EUR (203,11 USD).
ICON akcija (ICLR) tiek kotēta 4 biržās, tostarp: NASDAQ (ICLR), Frankfurt (IJF.F), München (IJF.MU), Düsseldorf (IJF.DU).
ICON plc is a leading global company in the field of clinical research and development of pharmaceuticals. It offers a wide range of services in clinical trials, consulting, strategy development, laboratory analysis, and data management. The company is divided into three main business areas: clinical development services, laboratory analysis, and data management. It works closely with its customers and partners to develop groundbreaking medications and treatments. ICON is known for its Enterprise Laboratory Information Management System (LIMS) and EDC solutions. It has a robust business model and is well-positioned for future growth.
gaidāmā apgrozījums ICON ir 8,16 B USD. Šis skaitlis ir balstīts uz pašreizējiem finanšu datiem un atspoguļo uzņēmuma biznesa sniegumu.
gaidāmā peļņa ICON ir 878,58 M USD. Neto peļņa atspoguļo uzņēmuma rentabilitāti pēc visu izdevumu atskaitīšanas.
ICON cenas un peļņas rādītājs (P/E) pašlaik ir 17,70. P/E rādītājs salīdzina pašreizējo akcijas cenu ar peļņu uz akciju un palīdz ieguldītājiem novērtēt ICON akcijas vērtību.
ICON cenas un apgrozījuma rādītājs (P/S) pašlaik ir 1,90. P/S rādītājs salīdzina tirgus kapitalizāciju ar gada apgrozījumu un kalpo kā ICON akcijas vērtības mērs.
ICON Eulerpool kvalitātes rādītājs ir 2/10.
ICON ISIN ir IE0005711209. ISIN (International Securities Identification Number) ir pasaulē unikāls vērtspapīru identifikators.
ICON WKN ir 932242. WKN (Wertpapierkennnummer) ir sešciparu vācu vērtspapīru identifikācijas numurs.
ICON tikeris ir ICLR. Tikeris tiek izmantots ICON akciju tirdzniecībai biržā.
ICON akcija
Visi ICON fundamentālie rādītāji un padziļinātā analīze
Mūsu akciju analīze par ICON ietver svarīgus finanšu rādītājus, piemēram, apgrozījumu, peļņu, P/E rādītāju, P/S rādītāju, EBIT, kā arī informāciju par dividendēm. Turklāt mēs aplūkojam aspektus kā akcijas, tirgus kapitalizāciju, parādus, pašu kapitālu un saistības no ICON. Ja meklējat sīkāku informāciju par šīm tēmām, piedāvājam detalizētas analīzes mūsu apakšlapās: